A case series of dermatomyositis following SARS-CoV-2 vaccination

Chan, Airiss R.; Tervaert, Jan Willem Cohen; Redmond, Desiree; Yacyshyn, Elaine; Ferrara, Giovanni; Hwang, Peter M.; Osman, M. S.; Gniadecki, Robert

doi:10.3389/fmed.2022.1013378

Cited by 13 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SC2V-related cerebrovascular diseases include VST, ischemic stroke, ICH, SAB, pituitary apoplexy, RCVS, cerebral vasculitis, and Susac syndrome ( Table 2 ) [ 4 , 6 …”

Section: Resultsmentioning

confidence: 99%

Neurological Adverse Reactions to SARS-CoV-2 Vaccines

Finsterer¹

2023

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

SARS-CoV-2 vaccines are not free of side effects and most commonly affect the central or peripheral nervous system (CNS, PNS). This narrative review aims to summarise recent advances in the nature, frequency, management, and outcome of neurological side effects from SARS-CoV-2 vaccines. CNS disorders triggered by SARS-CoV-2 vaccines include headache, cerebro-vascular disorders (venous sinus thrombosis [VST], ischemic stroke, intracerebral hemorrhage, subarachnoid bleeding, reversible, cerebral vasoconstriction syndrome, vasculitis, pituitary apoplexy, Susac syndrome), inflammatory diseases (encephalitis, meningitis, demyelinating disorders, transverse myelitis), epilepsy, and a number of other rarely reported CNS conditions. PNS disorders related to SARS-CoV-2 vaccines include neuropathy of cranial nerves, mono-/polyradiculitis (Guillain-Barre syndrome [GBS]), Parsonage-Turner syndrome (plexitis), small fiber neuropathy, myasthenia, myositis/dermatomyositis, rhabdomyolysis, and a number of other conditions. The most common neurological side effects are facial palsy, intracerebral hemorrhage, VST, and GBS. The underlying pathophysiology is poorly understood, but several speculations have been generated to explain the development of CNS/PNS disease after SARS-CoV-2 vaccination. In conclusion, neurological side effects develop with any type of SARS-CoV-2 vaccine and are diverse, can be serious and even fatal, and should be taken seriously to initiate early treatment and improve outcome and avoid fatalities. KEY WORDS: Side effects; COVID-19 vaccination; Neurological; Brain; Nerves."venous sinus thrombosis", "multiple sclerosis", "acute disseminated encephalomyelitis", "seizure", "Guillain Barre syndrome", "Parsonage Turner syndrome", "myositis", and "myasthenia". In addition, reference lists were searched for additional articles that matched the search criteria. Neurological COVID Vaccination Complications 223Table 1. Most common marketed anti-SARS-CoV-2 vaccines Company Generic name Brand name Ⓡ Technology Number of dosages Biontech Pfizer BNT162b2 Comirnaty m-RNA Two/booster Moderna m-RNA1273 Spikevax m-RNA Two/booster Astra Zeneca ChAdOx1-S nCoV-19 Vaxzevira Viral vector Two/booster Curevac CVnCoV Zorecimeran m-RNA Two Novavax NVX-Cov2373 Novaxovid Protein subunit Two Johnson & Johnson Ad26.COV.2S Jcovden Viral vector One Sinovac CoronaVac CoronaVac Viral vector Two/booster Valneva VLA2001 COVID-19 vaccine Viral vector Two/booster Sinopharm COVID 2019 vaccine BIBP Viral vector Two/booster Gam-Covid-Vac Sputnik-V Gam-Covid-Vac Viral vector Two Bharat Biotech BBV152 Covaxin Viral vector Two/booster CanSino Biologics Ad5-nCoV Convidecia Viral vector Single Sinopharm BBIBP32-CorV Covilo Viral vector Two booster Sanofi Pasteur VidPrevtyn beta VidPrevtyn beta Protein subunit OneOriginal articles and reviews published between 1966 and December 2022 were included. Abstracts, proceedings, and editorials were excluded from data analysis. The review does not claim to be complete, since the number of words and references was...

show abstract

“…SC2V-related cerebrovascular diseases include VST, ischemic stroke, ICH, SAB, pituitary apoplexy, RCVS, cerebral vasculitis, and Susac syndrome ( Table 2 ) [ 4 , 6 …”

Section: Resultsmentioning

confidence: 99%

Neurological Adverse Reactions to SARS-CoV-2 Vaccines

Finsterer¹

2023

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

show abstract

“…15 A cohort from Chan et al showed that, of 53 patients diagnosed with DM, 5 presented with symptoms after vaccination. 16 Other studies have seen a correlation between the vaccine and positivity of anti-MDA5 antibodies. 17,18 We performed a retrospective review in our institution to define the frequency of incident DM or a DM relapse following SARS-CoV-2 infection or COVID-19 vaccination.…”

Section: Introductionmentioning

confidence: 93%

“…The main autoantibodies found were anti‐TIF‐1‐γ, anti‐SRP, anti‐NXP‐2, anti‐Mi‐2, and anti‐Pm‐Scl 15 . A cohort from Chan et al showed that, of 53 patients diagnosed with DM, 5 presented with symptoms after vaccination 16 . Other studies have seen a correlation between the vaccine and positivity of anti‐MDA5 antibodies 17,18 …”

Section: Introductionmentioning

confidence: 99%

Dermatomyositis in Association With SARS‐CoV‐2 Infection or COVID‐19 Vaccine

Diaz‐Menindez,

Sullivan,

Wang

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveNew‐onset and relapsed dermatomyositis (DM) has been reported following SARS‐COV‐2 infection or COVID‐19 vaccination. This study aims to show the characteristics of a DM cohort after COVID‐19 infection and vaccination.MethodsA retrospective review was performed on patients treated between March 1, 2020, and October 31, 2022, for dermatomyositis. Charts were evaluated for the presence of new‐onset DM or relapse of preexisting DM following either SARS‐CoV‐2 infection or COVID‐19 vaccination. Data on symptoms onset, timing of vaccination, type of vaccination, and disease characteristics were collected.ResultsNinety‐eight patients treated for dermatomyositis at our institution in the Division of Rheumatology were included. In total 12/98 patients (12.2%) experienced DM symptoms (either incident or relapse) following either infection or vaccination. Of the 12 who developed incident disease or relapse, 7 (58.3%) patients developed symptoms post infection and 8 (66.7%) developed symptoms post‐vaccination (3 patients had symptoms following both infection and vaccination). The mean onset of symptoms following COVID‐19 infection was 3.2 days (median 0.5) and following COVID‐19 vaccination was 5.75 days (median 3.5). 9/12 (75%) patients had a positive myositis specific antibody and the remaining 3/12 (25%) had myositis‐associated antibodies. There was no predominant vaccine associated with the development of post‐vaccination DM symptoms.ConclusionThis retrospective review revealed a strong temporal relationship between dermatomyositis symptoms and COVID‐19 infection or vaccination in 12.2% of all DM patients evaluated in our clinic during the pandemic. Additional studies are required to understand the possible pathophysiology behind this association.

show abstract

“…Studies regarding SARS-CoV-2-induced IIM are lacking. Review of the literature yields mostly single case reports (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) , with larger case series referring to SARS-CoV-2 vaccines (21,22). Certainly, higher-level evidence is still required to discern whether the incidence of IIM has increased during the pandemic and whether the disease pattern and course have changed.…”

Section: Infectious Diseases Have Long Been Linked To the Development...mentioning

confidence: 99%

Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience

Kharouf

Kenig

Bohbot

et al. 2023

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

ObjectiveHigher-level evidence is required to discern whether the incidence of idiopathic inflammatory myopathies (IIM) has increased during the COVID-19 pandemic and whether the disease pattern and course have changed. We aimed to analyse patients who were diagnosed with IIM at our tertiary care centre during the pandemic and compare them with IIM patients diagnosed before COVID-19. MethodsWe retrospectively analysed the medical records of adult patients (>18 years) who were diagnosed with IIM during COVID-19 versus a control group of patients diagnosed before the outbreak. Included were patients whose diagnosis was made at the

show abstract

A case series of dermatomyositis following SARS-CoV-2 vaccination

Cited by 13 publications

References 37 publications

Neurological Adverse Reactions to SARS-CoV-2 Vaccines

Neurological Adverse Reactions to SARS-CoV-2 Vaccines

Dermatomyositis in Association With SARS‐CoV‐2 Infection or COVID‐19 Vaccine

Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience

Contact Info

Product

Resources

About